

# Computerized quantitative data integration of multi-protocol MRI for identification of high grade prostate cancer *in vivo*.


P. Tiwari<sup>1</sup>, J. Kurhanewicz<sup>2</sup>, and A. Madabhushi<sup>1</sup>

<sup>1</sup>Biomedical Engineering, Rutgers University, Piscataway, NJ, United States, <sup>2</sup>Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, United States

**Background:** In this work we present a novel multi-protocol MRI classifier, semi-supervised multi-kernel (SeSMiK), for quantitatively combining features from T2-w magnetic resonance (MR) imaging (T2-w MRI) and MR spectroscopy (MRS) data to identify high grade prostate cancer (CaP) *in vivo*. High grade CaP is known to be correlated with more biologically aggressive prostate cancer; low grade CaP is typically associated with indolent disease. Recently, Shukla et al. [1,2] have demonstrated, qualitatively, that improved differentiability between high and low grade CaP can be obtained using combined T2-w MRI, MRS compared to using the data individually. Choyke et al. [3] have suggested that there is need for quantitative computerized data fusion tools for integrating multi-parametric MRI in order to build classifiers to distinguish between high and low grade prostate cancer *in vivo*. A computerized decision support (CDS) tool that can distinguish high grade from low grade prostate cancer *in vivo* could help identify those patients who might benefit from a “wait and watch policy” as opposed to those who might be better suited to application of more aggressive treatment strategies. The objective of this work is to build a CDS classifier that can distinguish high from low grade prostate cancer *in vivo*, on a per voxel basis, using quantitative integration of T2-w MRI and MRS.

**Methods:** A total of 19 1.5 Tesla (T) T2-w MRI, MRS studies were obtained prior to radical prostatectomy. All of these studies were biopsy proven prostate cancer patient studies that were clinically referred for a prostate cancer MR staging exam for improved therapeutic selection. T2-weighted MR images were obtained by using the following parameters: 6000/96 (effective), an echo train length of 16, a 3-mm section thickness, no intersection gap, a 14-cm field of view, a  $256 \times 192$  matrix. MRS was acquired as  $16 \times 8 \times 8$  phase-encoded spectral arrays (1024 voxels) by using a nominal spectral resolution of  $0.24\text{--}0.34\text{ cm}^3$ , 1000/130, and a 17-minute acquisition time. An expert spectroscopist manually annotated individual MRS voxels across all studies as firstly (a) CaP/benign, and secondly, (b) as low ( $\leq 3+4$  Gleason score)/high ( $\geq 4+3$ ) grade CaP, and these per-voxel MRS annotations were used as a surrogate for ground truth in this study. The 19 studies comprised a total of (a) 573 CaP and 696 benign voxels, and (b) 175 low and 96 high grade CaP voxels. The SeSMiK strategy leverages multi-kernel learning (MKL) [4] and dimensionality reduction (DR) [5] to provide a unified framework for quantitative integration of T2-w MRI and MRS. Kernels capture the pairwise similarities between data points by transforming the input data into a dot product space, and DR homogeneously transforms the high-dimensional data into a low dimensional space by preserving local proximities between the data points. Our SeSMiK strategy comprises of following steps: (1) T2-w MRI texture features based on calculating responses to various gradient filter and gray level co-occurrence operators [6] are obtained along with MRS metabolic peak area features (choline, creatine, citrate, choline+creatine/citrate, choline/creatine), (2) Features extracted in Step (1) from T2-w MRI and MRS are transformed in a common kernel framework  $K_{MRI}$  and  $K_{MRS}$  respectively, to capture the pairwise similarities between data points across each modality, (3) a weighted combination of pairwise similarities from individual kernels is then obtained as  $\hat{K} = \beta K_{MRI} + (1 - \beta) K_{MRS}$ , where  $\beta$  is the weight assigned to T2-w MRI modality and, (4) the combined kernel  $\hat{K}$  obtained in Step (3) is high dimensional and thus cannot directly be used for classification. Hence a low dimensional representation of  $\hat{K}$  is obtained using a semi-supervised modification of a popular non-linear DR scheme called graph embedding (SSAGE) [5]. SSAGE incorporates partial labels to provide a better low dimensional representation of  $\hat{K}$  and hence improved separation between low and high grade prostate cancer.

**Results:** A probabilistic boosting tree (PBT) classifier which individually evaluated (1) T2-w MRI texture features, (2) MRS metabolic features, and (3) combined low dimensional features obtained via SeSMiK ( $\hat{K}$ ), was employed. Mean AUC for predicting high grade CaP over 25 iterations of randomized cross-validation were found to be, (a)  $0.79 \pm 0.03$  (T2-w MRI),  $0.83 \pm 0.03$  (MRS), and (c)  $0.87 \pm 0.02$  (SeSMiK). SeSMiK also demonstrated higher mean accuracy compared to individual T2-w MRI and MRS.



**Conclusion:** A novel CDS scheme employing SeSMiK is presented for distinguishing between low and high grade CaP *in vivo* via quantitative integration of T2-w MRI and MRS. The classifier was found to have a higher accuracy compared to the individual T2-w MRI, MRS modalities. Our results suggest that the SeSMiK classifier might be able to ultimately identify biologically aggressive CaP *in vivo*.

**References:** [1] A. Shukla-Dave, et al, *Radiology*, vol. 250, pp. 803-812, 2009. [2] D. L. Langer, et al, *Radiology*, vol. 255, pp. 485-494, 2010. [3] L. Choyke et al. *Nature Reviews*, vol. 6, pp. 191-203, 2009. [4] G. Lanckriet, et al. in *Proc. Pacific Symposium on Biocomputing*, vol. 9, pp. 300-311, 2004. [5] H. Zhao, *Neurocomputing*, vol. 69, pp. 2385-2389, 2006. [6] Viswanath, S. et al, in *Proc. SPIE*, 6915, pp. 69150U-12, 2008.